2019•Case Medical ResearchRequires access
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
Author information unavailable
Open publisher page 0 citations
Abstract
This record does not include an abstract. Use the full-text link above if available.